{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:32:22Z","timestamp":1793655142011,"version":"4.5.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":2351,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["HHSA 290-2012-00011I"],"award-info":[{"award-number":["HHSA 290-2012-00011I"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1111\/ajt.13710","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T20:50:40Z","timestamp":1458334240000},"page":"2117-2138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"D.","family":"Sawinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trofe\u2010Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Leas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tuteja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Umscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1111\/ajt.13710_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.13195","article-title":"OPTN\/SRTR 2013 annual data report: kidney","volume":"15","author":"Matas","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/TP.0b013e318195a421","article-title":"Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis","volume":"27","author":"Moore","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib3","unstructured":"Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. [AHRQ Publication No. 12-EGC047-EF]. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), 2012 [cited 2015 Jul 31]. Available from: www.effectivehealthcare.ahrq.gov\/"},{"key":"10.1111\/ajt.13710_bib4","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1111\/ajt.13710_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: A time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1111\/ajt.13710_bib6","first-page":"3417","article-title":"Application of low-dose calcineurin inhibitors in living-related donor renal transplantation","volume":"15","author":"Xu","year":"2011","journal-title":"J Clin Rehabil Tiss Eng Res"},{"key":"10.1111\/ajt.13710_bib7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.transproceed.2009.03.045","article-title":"Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine","volume":"41","author":"Spagnoletti","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib9","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"New Eng J Med"},{"key":"10.1111\/ajt.13710_bib10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/01.tp.0000282872.17024.b7","article-title":"Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression","volume":"84","author":"Hernandez","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib11","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/ndt\/gfl397","article-title":"Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy","volume":"21","author":"Tang","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.13710_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ijcp.12403","article-title":"A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients","volume":"181","author":"Cai","year":"2014","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1111\/ajt.13710_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/nep.12004","article-title":"Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients","volume":"18","author":"Chadban","year":"2013","journal-title":"Nephrology"},{"key":"10.1111\/ajt.13710_bib14","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1093\/ndt\/gfq135","article-title":"A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits","volume":"25","author":"Etienne","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.13710_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfp468","article-title":"Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation","volume":"25","author":"Fangmann","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.13710_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CNP67164","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab","volume":"67","author":"Budde","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1111\/ajt.13710_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1399-0012.2006.00622.x","article-title":"Renal function with cyclosporine C(2) monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients","volume":"21","author":"Cibrik","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.13710_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.transproceed.2007.03.014","article-title":"Low-dose versus high-dose cyclosporine induction protocols in renal transplantation","volume":"39","author":"Ghafari","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib20","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1111\/j.1600-6143.2006.01535.x","article-title":"Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The \u201creference\u201d study","volume":"6","author":"Frimat","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/ndt\/gfh188","article-title":"A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy","volume":"19","author":"Stoves","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.13710_bib22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/01.TP.0000061606.64917.BE","article-title":"A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation","volume":"75","author":"Pascual","year":"2003","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib23","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1681\/ASN.V1281750","article-title":"A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids","volume":"12","author":"De Sevaux","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.13710_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2012\/941640","article-title":"Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC-MPS","volume":"2012","author":"Chan","year":"2012","journal-title":"J Transplant"},{"key":"10.1111\/ajt.13710_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CN107227","article-title":"A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients","volume":"77","author":"Kamar","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1111\/ajt.13710_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0b013e31817442cf","article-title":"Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results","volume":"86","author":"Bolin","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.13710_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/tri.12228","article-title":"The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study","volume":"27","author":"Muhlbacher","year":"2014","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.13710_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"10.1111\/ajt.13710_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/TP.0000000000000225","article-title":"Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine A in de novo kidney recipients","volume":"99","author":"Oh","year":"2015","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","article-title":"Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial","volume":"93","author":"Paoletti","year":"2012","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.5301\/JN.2011.6247","article-title":"Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients","volume":"24","author":"Bertoni","year":"2011","journal-title":"J Nephrol"},{"key":"10.1111\/ajt.13710_bib35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib36","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib37","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.transproceed.2013.03.025","article-title":"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients","volume":"45","author":"Bechstein","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib38","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.13710_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","article-title":"Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation","volume":"18","author":"Lo","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.13710_bib41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study","volume":"83","author":"Budde","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1111\/ajt.13710_bib43","doi-asserted-by":"crossref","first-page":"e75591","DOI":"10.1371\/journal.pone.0075591","article-title":"Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial","volume":"8","author":"Bansal","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1111\/ajt.13710_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled spare-the-nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"key":"10.1111\/ajt.13710_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib46","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2005.01055.x","article-title":"A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib47","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1111\/ajt.12437","article-title":"Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen","volume":"13","author":"Chhabra","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib48","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1111\/ajt.12481","article-title":"Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients","volume":"13","author":"Silva","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","article-title":"Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal","volume":"92","author":"Heilman","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib50","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/ajt.13132","article-title":"Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA","volume":"15","author":"Rostaing","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib51","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mjornstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib52","first-page":"300","article-title":"Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up","volume":"6","author":"Nafar","year":"2012","journal-title":"Iran J Kidney Dis"},{"key":"10.1111\/ajt.13710_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib55","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/TP.0b013e318160d3c9","article-title":"Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor","volume":"85","author":"Durrbach","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib57","first-page":"649","article-title":"The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes","volume":"5","author":"Barsoum","year":"2007","journal-title":"Exp Clin Transplant"},{"key":"10.1111\/ajt.13710_bib58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/ajt.13710_bib59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1755.2003.00175.x","article-title":"Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy","volume":"64","author":"Bakker","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/ajt.13710_bib60","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/00007890-199811150-00013","article-title":"Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation","volume":"66","author":"MacPhee","year":"1998","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib61","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/00007890-199505150-00007","article-title":"The effect of immunosuppressive drugs on quality of life after renal transplantation","volume":"59","author":"Hilbrands","year":"1995","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.TP.0000151632.21551.00","article-title":"Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the \u201ccreeping creatinine\u201d study","volume":"79","author":"Dudley","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","article-title":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/ajt.13710_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/TP.0b013e31824ad60a","article-title":"Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal","volume":"93","author":"Mourer","year":"2012","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib65","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2008.02260.x","article-title":"Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells","volume":"8","author":"Pascual","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib66","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1600-6143.2004.00404.x","article-title":"Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy","volume":"4","author":"Suwelack","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib67","doi-asserted-by":"crossref","first-page":"E151","DOI":"10.1111\/ctr.12076","article-title":"Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial","volume":"27","author":"Asberg","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.13710_bib68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.tp.0000229424.11872.a0","article-title":"Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial","volume":"82","author":"Hazzan","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib69","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00007890-200212270-00015","article-title":"Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study","volume":"74","author":"Abramowicz","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1681\/ASN.V132536","article-title":"Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen","volume":"13","author":"Schnuelle","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.13710_bib71","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/01.ASN.0000013298.11876.BF","article-title":"Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study","volume":"13","author":"Smak Gregoor","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.13710_bib72","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/01.TP.0000057240.95073.35","article-title":"Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients","volume":"75","author":"Stallone","year":"2003","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib73","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/00007890-200212150-00013","article-title":"Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination","volume":"74","author":"Gonwa","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib74","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00007890-200109150-00007","article-title":"Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure","volume":"72","author":"Johnson","year":"2001","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib75","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib76","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s11255-011-0001-3","article-title":"Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus","volume":"43","author":"de Sandes Freitas","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/ajt.13710_bib77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib79","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib80","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000365671","article-title":"A prospective randomised paired trial of sirolimus versus tacrolimus as primary immunosuppression following non-heart beating donor kidney transplantation","volume":"7","author":"Asher","year":"2014","journal-title":"Curr Urol"},{"key":"10.1111\/ajt.13710_bib81","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib82","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib84","first-page":"295","article-title":"Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant","volume":"9","author":"Refaie","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"10.1111\/ajt.13710_bib85","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","article-title":"Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients","volume":"16","author":"Stallone","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.13710_bib86","first-page":"42","article-title":"Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study","volume":"9","author":"Han","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"10.1111\/ajt.13710_bib87","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.transproceed.2007.03.072","article-title":"Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy","volume":"39","author":"Liu","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib88","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.transproceed.2011.01.033","article-title":"Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study","volume":"43","author":"Pankewycz","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib89","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.transproceed.2009.08.065","article-title":"Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination","volume":"41","author":"Cataneo-Davila","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/nep.12368","article-title":"Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-(beta) signalling pathway in kidney transplant","volume":"20","author":"Rivelli","year":"2015","journal-title":"Nephrology"},{"key":"10.1111\/ajt.13710_bib91","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.transproceed.2012.07.142","article-title":"High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study","volume":"44","author":"Burkhalter","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib92","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1600-6143.2005.01064.x","article-title":"Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation","volume":"5","author":"Hamdy","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib93","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13710_bib94","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11255-014-0783-1","article-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis","volume":"46","author":"Su","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/ajt.13710_bib95","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10157-015-1109-z","article-title":"Effectiveness and safety of calcineurin inhibitor withdrawal in kidney transplantation: a meta-analysis of randomized controlled trials","volume":"19","author":"Bai","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1111\/ajt.13710_bib96","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.transproceed.2014.02.010","article-title":"Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Yan","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1111\/ajt.13710_bib97","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13710_bib98","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"10.1111\/ajt.13710_bib99","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362792","article-title":"Immunosuppressive medication adherence in kidney transplant patients","volume":"23","author":"Lalic","year":"2014","journal-title":"Med Princ Pract"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.13710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.13710","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522009273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522009273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.13710\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:12:05Z","timestamp":1761628325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522009273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1600613522009273"],"URL":"https:\/\/doi.org\/10.1111\/ajt.13710","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta\u2010Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.13710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}